title: Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks.
abstract: Glyceryl trinitrate, an exogenous nitric oxide (NO) donor, and histamine, which causes NO formation in vascular endothelium, have been shown to trigger migraine attacks. However, it remains uncertain whether NO is involved in the subsequent phase of migraine attacks. To answer this question we studied the effect of L-NGmethylarginine hydrochloride (546C88), a NO-synthase inhibitor, on spontaneous migraine attacks. In a double-blind study design, 18 patients with migraine without aura randomly received 546C88 (6 mg/kg) or placebo (5% dextrose) i.v. given over 15 min for a single migraine attack (546C88:placebo, 15:3). Furthermore, 11 placebo-treated patients from previous double-blind trials with almost identical design were added to the placebo group in the statistical evaluation. Two hours after the infusion, 10 of 15 L-NGmethylarginine hydrochloride-treated patients experienced headache relief compared to 2 of 14 placebo-treated patients (p = 0.01). Symptoms such as phono- and photophobia were also significantly improved. A similar trend for nausea was not significant. We conclude that NO may be involved in the pain mechanisms throughout the course of spontaneous migraine attacks.
authors.affiliation: Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark. l.h.lassen@image.dk
authors.forename: L H
authors.initials: LH
authors.lastname: Lassen
authors.forename: M
authors.initials: M
authors.lastname: Ashina
authors.forename: I
authors.initials: I
authors.lastname: Christiansen
authors.forename: V
authors.initials: V
authors.lastname: Ulrich
authors.forename: R
authors.initials: R
authors.lastname: Grover
authors.forename: J
authors.initials: J
authors.lastname: Donaldson
authors.forename: J
authors.initials: J
authors.lastname: Olesen
mesh_terms: D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000201:enzymology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D019323:omega-N-Methylarginine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004791:Enzyme Inhibitors; D019323:omega-N-Methylarginine; D019001:Nitric Oxide Synthase